- Home
- SEVN vs ABOS Comparison
SEVN vs ABOS Comparison
Compare SEVN & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEVN | ABOS |
|---|---|---|
| Founded | 1986 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.0M | 113.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SEVN | ABOS |
|---|---|---|
| Price | $8.92 | $1.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $12.83 | $7.67 |
| AVG Volume (30 Days) | ★ 176.0K | 168.5K |
| Earning Date | 02-17-2026 | 11-12-2025 |
| Dividend Yield | ★ 12.51% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $29,408,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.63 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.30 | $0.86 |
| 52 Week High | $13.97 | $2.46 |
Technical Indicators
Market Signals| Indicator | SEVN | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 46.04 | 47.64 |
| Support Level | $8.81 | $1.90 |
| Resistance Level | $9.03 | $2.39 |
| Average True Range (ATR) | 0.20 | 0.14 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 13.55 | 14.29 |
Price Performance
Historical ComparisonAbout SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.